Michael Green

Has grant

Assistant Professor

University of Michigan

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Michael Green is an Assistant Professor at the University of Michigan, USA. His research primarily focuses on areas such as cancer immunotherapy, biomarker development, and treatment strategies for non-small cell lung cancer. Recent publications include work on the prognostic role of PD-L1 expression and the contribution of lipid oxidation to radiotherapy efficacy. He actively contributes to advancing the understanding of immune responses in various cancer types.

Recent Grants

Grant: Close

Targeting Liver Metastases to Enhance Immunotherapy Efficacy in Melanoma

Open Date: 2021-06-01

Close Date: 2024-05-31

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Joseph Carmicheal

University of Nebraska Medical Center

UNITED STATES

View details

Michael J. Kelley

Duke University

UNITED STATES

View details

Garth Strohbehn

Assistant Professor

University of Michigan Rogel Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Green

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

Fat Fuels the Fire in Cervical Cancer

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma

Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer

The Liver–Immunity Nexus and Cancer Immunotherapy

Contribution of Lipid Oxidation and Ferroptosis to Radiotherapy Efficacy

It’s not ‘just a tube of blood’: principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies

Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

Collaborators (3)

Joseph Carmicheal

Michael J. Kelley

Garth Strohbehn

Make your next move.